Cargando…
The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences
Biosimilars are cheaper than original drugs and are thus of interest to the public. The aim of this article is to assess the benefits of introducing more than one biosimilar for the same substance (active pharmaceutical ingredient, API). The hypothesis is that the introduction of successive biosimil...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297232/ https://www.ncbi.nlm.nih.gov/pubmed/34209612 http://dx.doi.org/10.3390/ijerph18136952 |
_version_ | 1783725811622215680 |
---|---|
author | Barszczewska, Olga Piechota, Anna |
author_facet | Barszczewska, Olga Piechota, Anna |
author_sort | Barszczewska, Olga |
collection | PubMed |
description | Biosimilars are cheaper than original drugs and are thus of interest to the public. The aim of this article is to assess the benefits of introducing more than one biosimilar for the same substance (active pharmaceutical ingredient, API). The hypothesis is that the introduction of successive biosimilars of a specific original drug reduces the price of the selected API. The study focuses on drug prices varying with the successive arrival of new biosimilars. Three drugs that have at least three reimbursed biosimilars on the market were selected, two from the same therapeutic group (adalimumab and infliximab) and one (trastuzumab) representing another class of drugs. The following data were analyzed: price variation after the introduction of the first, second, and third biosimilar, and the average price reduction for all three biosimilars. Additionally, a literature review was conducted. The reimbursement of each new biosimilar is beneficial since it is associated with a price reduction in percentage terms. However, the first biosimilar brought about the greatest savings due to the higher initial prices of the original drugs and to Polish reimbursement rules. This article is helpful for when taking healthcare decisions regarding the pricing of and reimbursement for new biosimilars. |
format | Online Article Text |
id | pubmed-8297232 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82972322021-07-23 The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences Barszczewska, Olga Piechota, Anna Int J Environ Res Public Health Article Biosimilars are cheaper than original drugs and are thus of interest to the public. The aim of this article is to assess the benefits of introducing more than one biosimilar for the same substance (active pharmaceutical ingredient, API). The hypothesis is that the introduction of successive biosimilars of a specific original drug reduces the price of the selected API. The study focuses on drug prices varying with the successive arrival of new biosimilars. Three drugs that have at least three reimbursed biosimilars on the market were selected, two from the same therapeutic group (adalimumab and infliximab) and one (trastuzumab) representing another class of drugs. The following data were analyzed: price variation after the introduction of the first, second, and third biosimilar, and the average price reduction for all three biosimilars. Additionally, a literature review was conducted. The reimbursement of each new biosimilar is beneficial since it is associated with a price reduction in percentage terms. However, the first biosimilar brought about the greatest savings due to the higher initial prices of the original drugs and to Polish reimbursement rules. This article is helpful for when taking healthcare decisions regarding the pricing of and reimbursement for new biosimilars. MDPI 2021-06-29 /pmc/articles/PMC8297232/ /pubmed/34209612 http://dx.doi.org/10.3390/ijerph18136952 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Barszczewska, Olga Piechota, Anna The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences |
title | The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences |
title_full | The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences |
title_fullStr | The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences |
title_full_unstemmed | The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences |
title_short | The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences |
title_sort | impact of introducing successive biosimilars on changes in prices of adalimumab, infliximab, and trastuzumab—polish experiences |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297232/ https://www.ncbi.nlm.nih.gov/pubmed/34209612 http://dx.doi.org/10.3390/ijerph18136952 |
work_keys_str_mv | AT barszczewskaolga theimpactofintroducingsuccessivebiosimilarsonchangesinpricesofadalimumabinfliximabandtrastuzumabpolishexperiences AT piechotaanna theimpactofintroducingsuccessivebiosimilarsonchangesinpricesofadalimumabinfliximabandtrastuzumabpolishexperiences AT barszczewskaolga impactofintroducingsuccessivebiosimilarsonchangesinpricesofadalimumabinfliximabandtrastuzumabpolishexperiences AT piechotaanna impactofintroducingsuccessivebiosimilarsonchangesinpricesofadalimumabinfliximabandtrastuzumabpolishexperiences |